Tesofensine: The Triple Monoamine Reuptake Inhibitor for Advanced Weight Management Studies

What is Tesofensine?

While peptides dominate the GLP-1 and triple-agonist landscapes, Tesofensine (NS2330) represents a highly innovative, non-peptidic small molecule. It is classified as a potent Triple Monoamine Reuptake Inhibitor (TRI), originally researched for neurodegenerative conditions and subsequently repurposed for advanced metabolic studies.

Triple Reuptake Inhibition Pathways

Tesofensine works by blocking the presynaptic reuptake transporters for three critical neurotransmitters:

• Noradrenaline (Norepinephrine): Stimulates the sympathetic nervous system, boosting energy expenditure and fat breakdown.
• Dopamine: Regulates the brain’s reward center, reducing cravings for palatable foods.
• Serotonin: Coordinates satiety signals, helping to reduce overall food consumption in trial models.

Laboratory Efficacy Profile

In animal assays, Tesofensine has demonstrated the ability to produce weight loss that is up to twice as powerful as older metabolic agents. It achieves this by combining active metabolic thermogenesis with highly effective appetite regulation, making it a key compound for metabolic research.